Zhongyuan Wang , Wenhao Xu , Fangning Wan , Xi Tian , Aihetaimujiang Anwaier , Shiqi Ye , Siqi Zhou , Hailiang Zhang , Xiaojian Qin , Dingwei Ye
{"title":"中国前列腺癌:流行病学趋势、基因组学见解和优化管理的未来方向","authors":"Zhongyuan Wang , Wenhao Xu , Fangning Wan , Xi Tian , Aihetaimujiang Anwaier , Shiqi Ye , Siqi Zhou , Hailiang Zhang , Xiaojian Qin , Dingwei Ye","doi":"10.1016/j.jncc.2025.05.002","DOIUrl":null,"url":null,"abstract":"<div><div>The incidence and mortality of prostate cancer (PCa) in China have risen sharply in recent years, posing an escalating public health concern. In contrast to Western populations, Chinese patients are more frequently diagnosed at advanced stages, often with metastatic disease and suboptimal survival outcomes. These disparities reflect intrinsic differences in epidemiological patterns, molecular landscapes, and healthcare delivery systems unique to the Chinese context. Nevertheless, prevailing PCa management paradigms, largely derived from Western-centric evidence, remain inadequately calibrated to the biological and clinical realities of Chinese patients. This review provides a comprehensive synthesis of the epidemiology, genomic alterations, clinical presentations, and treatment disparities of PCa in China, highlighting the urgent need for population-specific strategies. Priority areas include the development of ethnically optimized screening protocols, the integration of precision medicine approaches, and the implementation of regionally adapted prevention and early detection programs. Furthermore, expanding participation in clinical trials and accelerating translational research efforts, particularly in multi-omics and biomarker discovery, will be critical to bridging current gaps. By aligning emerging scientific innovations with localized healthcare needs, China holds the potential to reshape its prostate cancer care paradigm, improving outcomes, reducing disparities, and contributing to the global advancement of precision oncology.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"5 5","pages":"Pages 474-485"},"PeriodicalIF":9.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prostate cancer in China: epidemiological trends, genomic insights, and future directions for optimized management\",\"authors\":\"Zhongyuan Wang , Wenhao Xu , Fangning Wan , Xi Tian , Aihetaimujiang Anwaier , Shiqi Ye , Siqi Zhou , Hailiang Zhang , Xiaojian Qin , Dingwei Ye\",\"doi\":\"10.1016/j.jncc.2025.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The incidence and mortality of prostate cancer (PCa) in China have risen sharply in recent years, posing an escalating public health concern. In contrast to Western populations, Chinese patients are more frequently diagnosed at advanced stages, often with metastatic disease and suboptimal survival outcomes. These disparities reflect intrinsic differences in epidemiological patterns, molecular landscapes, and healthcare delivery systems unique to the Chinese context. Nevertheless, prevailing PCa management paradigms, largely derived from Western-centric evidence, remain inadequately calibrated to the biological and clinical realities of Chinese patients. This review provides a comprehensive synthesis of the epidemiology, genomic alterations, clinical presentations, and treatment disparities of PCa in China, highlighting the urgent need for population-specific strategies. Priority areas include the development of ethnically optimized screening protocols, the integration of precision medicine approaches, and the implementation of regionally adapted prevention and early detection programs. Furthermore, expanding participation in clinical trials and accelerating translational research efforts, particularly in multi-omics and biomarker discovery, will be critical to bridging current gaps. By aligning emerging scientific innovations with localized healthcare needs, China holds the potential to reshape its prostate cancer care paradigm, improving outcomes, reducing disparities, and contributing to the global advancement of precision oncology.</div></div>\",\"PeriodicalId\":73987,\"journal\":{\"name\":\"Journal of the National Cancer Center\",\"volume\":\"5 5\",\"pages\":\"Pages 474-485\"},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Cancer Center\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266700542500050X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Center","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266700542500050X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prostate cancer in China: epidemiological trends, genomic insights, and future directions for optimized management
The incidence and mortality of prostate cancer (PCa) in China have risen sharply in recent years, posing an escalating public health concern. In contrast to Western populations, Chinese patients are more frequently diagnosed at advanced stages, often with metastatic disease and suboptimal survival outcomes. These disparities reflect intrinsic differences in epidemiological patterns, molecular landscapes, and healthcare delivery systems unique to the Chinese context. Nevertheless, prevailing PCa management paradigms, largely derived from Western-centric evidence, remain inadequately calibrated to the biological and clinical realities of Chinese patients. This review provides a comprehensive synthesis of the epidemiology, genomic alterations, clinical presentations, and treatment disparities of PCa in China, highlighting the urgent need for population-specific strategies. Priority areas include the development of ethnically optimized screening protocols, the integration of precision medicine approaches, and the implementation of regionally adapted prevention and early detection programs. Furthermore, expanding participation in clinical trials and accelerating translational research efforts, particularly in multi-omics and biomarker discovery, will be critical to bridging current gaps. By aligning emerging scientific innovations with localized healthcare needs, China holds the potential to reshape its prostate cancer care paradigm, improving outcomes, reducing disparities, and contributing to the global advancement of precision oncology.